Skip to main content

Table 1 Protein tumor marker concentrations among the investigated patients with metastatic breast cancer and healthy females

From: Detection and monitoring of hypermethylated RASSF1A in serum from patients with metastatic breast cancer

  CA 15-3 (mean ± SE, n = 24) CEA (mean ± SE, n = 24) TPA (mean ± SE, n = 24)
Patients with metastatic breast cancer 1552 ± 384 kU/La 559.7 ± 177 μg/La 2639 ± 657 U/La
Age-matched healthy females 14.4 ± 1.1 kU/L 3.1 ± 0.3 μg/L 56.8 ± 10.8 U/L
  1. aSignificantly different from age-matched control concentration (p < 0.05). The serum samples were used to isolate DNA, which was used to calculate the sensitivity and specificity of six different primer designs against hypermethylated RASSF1A